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Since it was first described, the imprinted cluster 11p15.5 has been reported to be deregulated in a variety of
pediatric and adult cancers including that of the lung. Both protein coding and non-coding genes functioning as
oncogenes or as tumor suppressor genes reside within this cluster. Oncomirs that can function as oncogenes or as
tumor suppressors have also been reported. While a complete account of the role played by the 11p15.5 imprinted
cluster in lung cancer is beyond the scope of this review, we will focus on the role of the non-coding RNAs processed
from the H19-IGF2 loci. A special emphasis will be given to the H19/miR-675 gene locus. Their potential diagnostic and
therapeutic use in lung cancer will be described.
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Lung cancer is the leading cause of cancer death among
men and women. The prognosis of most lung cancer
patients, afflicted with either non-small-cell lung cancer
(NSCLC) or small cell lung cancer (SCLC), is dismal.
Survival is low; the poor U.S. survival rate of 15% at 5
years is even lower in Europe and rest of the world. The
unfavorable outcome is mainly due to our relatively
limited understanding of the molecular pathogenesis
of this cancer. A greater knowledge of lung cancer’s
molecular processes may yield accurate new biomarkers
for this disease and lead to its molecular diagnosis and risk
stratification. For a long time, chemotherapy has been
the main treatment. Classic chemotherapy was designed
to block cellular replication, mainly by interrupting
DNA synthesis and mitotic division. However, the
clinical outcome of this approach has not provided
reasons for optimism [1]. Recent advances in the under-
standing of the molecular aspects of the process of
tumorigenesis have allowed identification of certain
molecular targets for cancer treatment. Currently classic
chemotherapy is being combined with tyrosine kinase* Correspondence: imad.matouq@mail.huji.ac.il
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unless otherwise stated.inhibitors, such as erlotinib and gefitinib, or with mono-
clonal antibodies such as bevacizumab.
A meta-analysis of the impact of bevacizumab treat-
ment found that an overall survival benefit in lung can-
cer was seen [2]; however the overall survival was still
low. This frustrating state-of-the–art emphasizes the
importance of the search for innovative treatments.
Translational research was at first to a large extent
based on oncogenes, tumor suppressor genes and their
products. Later on, growth signal transduction, medi-
ated by specific membrane receptors, moved to the
forefront of such research. Only recently, long non-
coding RNA (lncRNA) and microRNA (miRNA) genes
have started to get a wider recognition as an important
part of the molecular origin of cancer [3-5].The emerging roles of non-coding RNA (ncRNA) genes in
lung cancer
While this section is not meant to be a comprehensive list
of the roles of ncRNAs in lung cancer, we will use specific
examples to illustrate the way that lncRNA’s generalized
modes of action can occur via diverse mechanisms.
While less than 2% of our DNA is translated, the vast
majority of the genome is actively transcribed producing
various types of ncRNA, including the long RNAs (>200
nucleotides) and miRNA.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pect of ncRNA research. Many thousands of lncRNAs
are produced from our genome, yet relatively few have
well documented roles in tumorigenesis and even
fewer have been reported to have roles in lung cancer.
Examples of lncRNA genes having roles in lung
tumorigenesis are H19, metastasis associated lung
adenocarcinoma transcript 1 (MALAT1), smoke and
cancer-associated lncRNA-1 (SCAL1), lncRNA-LET,
intronic ncRNA AK126698, BC-200 and hox transcript
antisense intergenic RNA (HOTAIR) [6-11].
LncRNA genes have developmental and tissue specific
expression patterns and aberrant regulation in a variety
of diseases, including cancer. lncRNAs regulate the
expression either of their neighbouring genes in cis, or
of more distant genes in trans.
Some lncRNAs have been associated with a spectrum
of biological processes including epigenetics and chro-
matin modifications. HOTAIR is perhaps a relatively
well understood example. HOTAIR can bind to poly-
comb repressive complex 2 (PRC2) and thus regulate
gene expression by directing the polycomb protein
group to target DNA regions, inducing changes in his-
tone marks and chromatin structure and ultimately sup-
pressing transcriptional activity [12]. Forced expression
of HOTAIR enhances lung cancer cell migration and
anchorage-independent cell growth and is associated
with short disease-free survival in NSCLC [13]. Further-
more, HOTAIR contributes to cisplatin resistance of
human lung adenocarcinoma cells via down-regulation
of p21(WAF1/CIP1) expression [14].
Other lncRNAs perform their function, at least in part,
by being precursors for miRNA. Several miRNAs have
been reported to be hosted in the exons or introns of
some lncRNA [15,16], including also imprinted lncRNA
[17]. In a study aimed to identify novel imprinted genes
Hagan et al., identified at least ten genes define the
imprinted DlK1-Dio3 cluster located on mouse chromo-
some 12qF1. Seven imprinted non-coding RNAs with
maternal expression (Meg3/Gtl2, Anti-peg11, Meg8,
Irm/“Rian”, AK050713, AK053394 and Meg9/Mirg) have
being identified, the majority of them contain miRNA
and/ or snoRNAs in their introns as do their human
orthologs [17]. The H19 lncRNA can serve also as a pre-
cursor for a miRNA (miR-675), and will be discussed in
later sections [18]. Furthermore, Xia et al. have demon-
strated recently that some lncRNAs can regulate gene
expression and thus contribute to oncogenesis by acting
as competing endogenous RNA or molecular sponges for
miRNA thus having the potential to scavenge miRNA
targets. Eight lncRNAs including H19 were identified as
using this mode of action [19]. In addition some
lncRNAs can function as antisense transcripts. Several
sense/antisense pairs have been identified in lung cancerand are significantly associated with multiple clinopatho-
logical factors. Two such examples are NKX2-1-AS1/
TTF1, and DSCAM-AS1/DSCAM [20].
Other lncRNAs can regulate alternative splicing, cell
cycle regulation and nuclear import [21], in addition to
being associated with structural components as precur-
sors to small RNAs and even as regulators of mRNA
decay [22].
lncRNAs can act also in cis; for example allelic im-
printing depends on lncRNAs that mediate the silencing
of neighboring genes. H19 lncRNA also belongs to this
category [23].
Furthermore lncRNA expression may provide clinical
information regarding disease etiology and so could be
used in diagnostic tests. In lung cancer, a recent study
identified 72 lncRNAs that are associated with tumor
subtypes [24]. The characterization of such RNA species,
from function to clinical applicability, is of major bio-
logical and clinical importance.
Several recent studies have examined the association
between lncRNA expression and cancer. A group of
lncRNAs having differential expression in NSCLC tumors
and in normal tissue has been identified. Upregulation of
lncRNA was found to be strongly correlated with poor
prognosis and high invasion and migration activity [25]. A
group of 111 lncRNAs termed lung cancer-associated
lncRNA (LCALs) have been identified that show differen-
tial expression in both adenocarcinoma and squamous cell
carcinoma when compared with matched controls [26].
Interestingly, the expression levels of many LCALs have
significant associations with the mutational status of key
oncogenes in lung cancer. The function of the majority of
these LCALs is yet to be elucidated.
MiRNAs are short (21–23 nucleotides) single-strand
non-coding RNA molecules whose important role in
neoplasia has unfolded over recent years. A miRNA
molecule exerts negative control on mRNA by annealing
to a complementary sequence, which results in protein
translation inhibition or mRNA degradation [27]. A
miRNA can assume the role either of a tumor suppres-
sor gene (TSG) when it targets an oncogene, or that of
an oncogene, if it’s critical target is a TSG.
Important gene products playing a pivotal role in lung
cancer have been reported to be targets of miRNAs. Let-7,
miR-34 families, and miR-17-92 among others have
already been shown to play important roles in lung
cancer [28].
One of the miRNAs with a role in the pathogenesis of
lung cancer is let-7. The RAS oncogene is targeted by
members of the let-7 miRNA family, which are often
under expressed or deleted in lung cancer, thus facilitat-
ing RAS over expression. Let-7 family members have
recently been shown to be oncofetal miRNAs, playing a
role both during human lung development and in its
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that let-7 functionally inhibits non-small cell tumor
development. In addition they have reported that over-
expression of let-7 g caused significant growth reduc-
tion in human non-small cell lung tumors [29]. Another
report has shown that let-7c inhibits invasion and mi-
gration of human NSCLC by targeting ITGB3 and
MAP4K3. This study measured the expression of let-7
members in NSCLC tumors and a significant associ-
ation was noticed between low levels of let-7c expres-
sion and patients with metastasis [30].
Another miRNA family of relevance to lung cancer is
miR-29, which is also under expressed in this malig-
nancy. When expression is induced under experimental
conditions by blocking specific methyltransferases, normal
patterns of DNA methylation are restored and previously
silenced TSG such as FHIT are now expressed [31].
Low expression levels of miR-34a (a transcriptionally
induced target for p53) has been reported in lung cancers
as well as in many other types of cancers, and low expres-
sion level correlate with high probability of relapse in
NSCLC patients. Therapeutic approaches to the treatment
of NSCLC based on miRNA are in pre-clinical develop-
ment. Systemic delivery of the synthetic tumor suppressor
miR-34 in a lipid-based vehicle in an approach called
miRNA replacement therapy blocks tumor growth in
mouse models, was well tolerated and did not induce an
immune response indicating the safety of this approach
[32]. This approach has also proved successful for let-7
replacement in reducing tumor growth in mouse models
of lung cancer [33].
11p.15.5 miRNAs and lung cancer
To the best of our knowledge, three miRNAs processed
from the 11p15.5 cluster have been discovered to date,
namely miR-675 and miR-483 belonging to the H19-
IGF2 loci, and miR-210. While each of these miRNAs
has its own targets, it is noticeable that all of them are
modulated by hypoxic stress, a common feature of the
tumor microenvironment, and contribute to the repres-
sion of biologically important genes. It is possible that
11p15.5 miRNAs contribute to tumor progression by
accommodating cancer cells to the otherwise lethal hyp-
oxic microenvironment.
Although IGF2 was up-regulated by hypoxic stress and
can promote angiogenesis through the IGF2 receptor in
vascular endothelial cells, miR-483-5p, which is proc-
essed from IGF2 intron 2, was down-regulated. It acts as
an endogenous angiogenesis inhibiting factor, at least in
part through targeting serum response factor (SRF), which
is required for angiogenesis [34]. Up-regulation of miR-
483-5p correlates with the progression of human lung
adenocarcinoma. MiR-483 is activated by the Wnt-β
catenin signaling pathway and directly targets twoputative metastatic suppressor proteins, Rho GDP dissoci-
ation inhibitor alpha (RhoGDI1) and activated leukocyte
cell adhesion molecule (ALCAM) to promote epithelial
to mesenchymal transition (EMT) [35].
An H19-related miRNA is miR-675, which is processed
from H19 exon 1 [18]. Hypoxia up-regulated the expres-
sion level of miR-675 along with H19 RNA. We recently
reported that under hypoxic stress miR-675 was elevated
and so promoted the EMT process [36]. Furthermore,
in hypoxic human articular chondrocytes, miR-675 is
induced in a Sox-9 dependent manner and promotes
the induction of Col2aI cartilage matrix gene [37].
Encoding miR-675 is one of the important roles of
H19 RNA. MiR-675 is expressed exclusively in the
placenta from the gestational time point at which placen-
tal growth normally ceases. The physiological role for
miR-675 is to limit placental overgrowth, at least in part
by targeting igf1r [38]. In cancer, a seemingly contradict-
ory function is attributed to miR-675. In colorectal cancer
cells for example, miR-675 targets retinoblastoma (RB)
so boosting cellular proliferation [39]. In human gastric
cancer miR-675 enhances cell proliferation by targeting
the tumor suppressor RUNX1 [40]. It remains to be estab-
lished how miR-675 target selection is accomplished in
both the physiological and the pathological state.
We recently showed that miR-675 is important in the
up-regulation of Slug expression through an unknown
target. E-cadherin expression is abolished, resulting in
the induction of EMT in many cancer types including
lung cancer [36]. These findings are in agreement with
the report that miR-675 promotes invasion in glioma
cells by directly targeting CDH13 [41]. CDH13 is a
tumor suppressor gene and its down-regulation is im-
portant step in the progression of lung cancer [42].
Recently, Wang et al. analyzed miRNA profiles in lung
cancer patients. In this study they found that miR-675
was up-regulated significantly and has a major role in
lung cancer through its regulation of its target genes, in
particular RB1 [43].
Perhaps the best understood role in hypoxic stress is
that of miR-210. It was shown that HIF-1 induction of
miR-210 stabilizes HIF-1 through a positive regulatory
loop. MiR-210 is up-regulated in lung cancer as well as
in other types of cancers and over-expressed at late
stages of NSCLC [44]. Moreover, miR-210 increases the
resistance of hypoxic lung cancer cells to radiotherapy
through HIF-1 and may be involved in promoting effi-
cient genomic double strand breaks [45]. Validated tar-
gets of miR-210 include genes functioning in various
aspects of tumorigenesis including cell cycle regulation
and apoptosis, DNA damage repair, angiogenesis mito-
chondrial metabolism and antitumor immune response
[46]. Its role in cancer is under debate as well as its
prognostic impact [47,48].
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H19 was the first lncRNA gene discovered [49] and is
paternally imprinted. In humans, H19 maps to chromo-
some 11p15.5, in close proximity to the reciprocally
imprinted IGF2 gene. It transcribes a 2.3 KB non-coding
RNA transcript by RNA polymerase II and splices to five
exons. Alternatively spliced variants have been also
reported, however the significance of this alternative
splicing is still unknown. One such variant was reported
by our group to have restricted expression in embryonic
tissues but not neoplastic ones [50]. H19 is highly
expressed throughout development of the embryo and
fetus, and also to the large extent in the placenta, but is
shut down in most tissues shortly after birth.
In recent years it has become increasingly clear that
the H19 gene locus is far more complicated than initially
thought. H19 opposite tumor suppressor (HOTS), a pro-
tein coded by the H19 antisense transcript and that has
tumor suppressor activity has been described recently.
Another relatively very long (~120 KB) and short lived
transcript called 91H spans the H19 gene locus and pos-
sesses tumor promoting activity, and is transcribed also
in an antisense direction. Furthermore, the H19 tran-
script itself gives rise to the oncomir miR-675 which is
processed from its first exon. The relations between
these different products and how they are deregulated in
the context of tumorigenesis remain to be elucidated
(for review see [51]).
The principal characteristics of imprinted genes are
their onco-fetal behavior pattern and their uniparental
mono allelic expression [52]. In several human cancers,
both pediatric and adult, release of imprinting underlies
gene expression. This alteration was identified as a loss
of imprinting (LOI). H19 lncRNA can be over-expressed
via the LOI mechanism. This was found in a variety of
malignancies, but not all. The significance of H19 LOI in
cancer is not well understood.
H19 expression is induced by chemical carcinogens,
retinoic acid, steroid and peptide hormones, growth
factors such as hepatocyte growth factor (HGF), tissue
repair factors, cytokines, and hypoxic stress [51].
Furthermore, we and others have identified various
transcription factors such as E2F [53], HIF-1α [54], Slug
[36], p53 [54,55] and c-myc [56] that can modulate H19
gene expression. Dysregulated activity of these transcrip-
tion factors can affect many aspects of tumor biology
including lung tumorigenesis.
Recent reports have linked H19 lncRNA to various
fundamental pathways known to be involved in tumori-
genesis, including the p53 and HIF-1α [54], hedgehog
[57], TGF-β [36], Bcr-Abl [58], RB-E2F1 [39,40,53],
HGF (MET) [59] and Wnt/β-catenin signaling pathways
(Figure 1). The Wnt/β-catenin pathway is activated byH19 lncRNA when associated with enhancer of zeste
homolog 2 (EZH2), and this resulted in down-regulation
of E-cadherin [60].
Furthermore it was shown that H19 lncRNA can
modulate chromatin structure within the imprinted
gene network through association with methyl-CpG-
binding domain protein 1 (MBD1) [23]. Recently, H19
lncRNA was demonstrated to function as an endogen-
ous sponge for miRNA [19]. It was further shown that
H19 RNA can function as a molecular sponge for let-7
tumor suppressor miRNA, as it harbors both canonical
and non-canonical binding sites for the let-7 family
of miRNAs [61]. Consequently, H19 relieves let-7′s
inhibitory effect on the oncogene Hmga2 [62]. H19
lncRNA is thus emerging as one of the key players in
cancer biology. Figure 2 summarizes various validated
and possible modes through which H19 lncRNA can
function [18,23,36,39-41,60-66].
We have identified hypoxia as a principal inducer of
H19 lncRNA [54,67]. H19 lncRNA functions, conse-
quently, as a stress modulator and a survival factor and is
involved in several fundamental processes triggered by
hypoxia including EMT, metastasis and neo-angiogenesis
[36,54,68]. EMT is an important process on the way to the
malignant phenotype; notably H19 up-regulation occurs
in the stroma as well as in the epithelium [69]. In the
metastatic tumor stage, which bears a striking similarity
to the embryonic stage, H19 involvement appears to be
essential: adherent and cohesive cells lose their anchor-
age, migrate under stressful conditions to remote sites
and replicate with neovascular support.
In lung cancer cells, H19 is induced upon hypoxic
stress in a p53-dependent manner. Reconstitution of a
wild type p53 in lung cancer cells possessing a null p53
mutation, abrogates H19 induction by hypoxia. The
effect of p53 is nuclear but independent of its tetrameri-
zation, which is needed for its transcriptional activity.
Knocking down H19 lncRNA in hypoxia inhibits lung
cancer cell proliferation. For lung cancer cells possessing
wild type p53, simultaneous inhibition of p53 and over-
expression of HIF1-α were needed to upregulate H19
lncRNA significantly upon hypoxia [54].
In an attempt to understand the oncogenic role of H19
lncRNA in lung cancer, we utilized siRNA-mediated
knockdown of H19. This approach resulted in very sig-
nificant suppression of anchorage-independent growth,
as assessed by colony formation in soft agar, implying
that H19 lncRNA is functioning as an oncogene [36,67].
Most importantly, we provided strong evidence showing
that the tumorigenic and scattering effect of HGF/SF on
the A549 lung carcinoma cells can be attenuated by
H19 knockdown [36]. Both HGF and its receptor, the
MET tyrosine kinase, are overexpressed in lung cancer
and as such are targets for therapeutic interventions.
Figure 1 Validated signaling pathways that modulate H19 lncRNA expression. Shown are different signaling pathways reported recently
that modulate the H19 lncRNA expression. Inside the circle are upstream transcription factors and signal transducers that modulate H19 lncRNA
expression. Outside the circle are the downstream targets of either H19/miR-675. These signaling pathways play different fundamental roles in
tumor biology including lung tumorigenesis.
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trial and have been shown to be active against lung
cancer (for review see [70]).
Furthermore, we recently provided evidence that H19
lncRNA significantly promotes the metastasis of lung
cancer cells in vivo. This could be explained at least in
part by the ability of H19 lncRNA to suppress the ex-
pression of E-cadherin and thus promote the EMTFigure 2 Validated/possible patterns through which H19 lncRNA can
imprinting of IGF2 by competing for common enhancers located downstre
through various patterns illustrated above. The possibility that H19 can funprocess by up-regulating Slug expression through a
mechanism that involves miR-675 [36].
Further support for the involvement of H19 in lung
cancer can be found in other reports. It was revealed
that H19 lncRNA is over-expressed in lung cancer due
to the loss of imprinting [71]. In addition, we reported
that various cancers that metastasized to the lung show
high expression levels of H19 lncRNA [36].perform its function. The H19 gene can function in cis to control the
am of H19 gene. In trans H19 lncRNA was reported to function
ction as an antisense transcript for HOTS is still not proven.
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c-Myc has been found in a panel of 240 NSCLC tumors.
c-Myc binds to evolutionarily conserved E-boxes near the
imprinting control region to facilitate histone acetylation
and transcriptional initiation of the H19 promoter. It was
deduced from this study that c-Myc induction of H19
plays an important role in transformation process [56].
Strong support for the linkage between lung cancer
development and H19 lncRNA expression was provided
by a study that revealed that smokers have dramatically
elevated H19 lncRNA levels without alternation of the
expression levels of other imprinted genes in the cluster.
The up-regulation of H19 was monoallelic and it was
suggested that overexpression and eventual LOI of H19
may represent early markers in the progression of airway
epithelium toward lung cancer [72].
Recently it was revealed that mineral dust-induced
gene (mdig) enhances H19 expression by influencing the
heterochromatin structure through reduction in the level
of H3K9me3 in the promoter as well as ICR region of
the H19 gene in adenocarcinoma lung cancer cells [73].
Lung cancer patients with high expression levels of mdig
and H19 manifest poorer survival. Initially mdig was
identified in people exposed to mineral dust in the min-
ing industry and have chronic lung disease.
Other lncRNA of the H19-IGF2 axis
Two other lncRNA transcripts that are antisense to both
H19 and IGF2 have been documented. 91H is a long and
relatively unstable lncRNA which spans H19 in antisense
direction and is over-expressed in breast cancer [74]. It
contributes to IGF2 activation in trans and promotes
tumor metastasis and predicts poor prognosis in colo-
rectal cancer [75]. IGF2-AS is transcribed antisense to
IGF2. This transcript is also maternally imprinted and
overexpressed in Wilms’ tumor [76]. The roles of both
transcripts in lung cancer have yet to be elucidated.
H19 and mir-675 as tools for diagnosis and prognosis in
lung cancer
To increase the survival of lung cancer patients we need
to improve the sensitivity of the diagnostic methods; the
earlier the diagnosis, the more effective the treatment. In
general, the development of molecular biology methods
has improved the early detection of malignancy. These
methods also aid in providing a more accurate prognosis
and in choosing the best treatment options. These
advantages are also valid for lung malignancies.
The molecular characterization of lung tumors has
increased the available options for noninvasive methods
of diagnosis. Over the last decade the use of body fluids
for lung tumor diagnosis has become common. This
resulted in significant decrease of the usage of invasive
methods.Lung cancer is one of types of cancer in which many
lncRNAs or miRNA molecules are found in blood (plasma/
serum), free or inside exosomes [77-79]. In addition many
studies have searched for a miRNA in sputum that is
specific to lung cancer patients [80,81]. The high ex-
pression of H19 and miR-675 in lung tumors suggest
that they could be used to detect lung cancer in fluid
body like sputum (this has not yet been attempted).
However, miR-675 has been recently shown to be se-
creted via the exosome [82]. The diagnostic and prog-
nostic potential needs to be evaluated.
Therapeutic implications
A. Targeted personalized medicine
H19 is commonly expressed in human lung cancer,
but a given percentage of the patients are expected
to be negative. The first stage should be the exclusion
of H19 negative patients. We have gained relevant
experience from the treatment of bladder transitional
cell cancer (TCC) patients, where a phase I/IIB
clinical trial has already been completed [83]. Patient
selection is achieved using labeled H19 riboprobe
in-situ hybridization of tumor samples. Expression
intensity is quantified by a computerized histogram.
Normal epithelia and the tumor carcinomatous as well
as its stromal components can easily be distinguished.
Exfoliated cells may also be informative using this
technique; however, good-size tumor samples are
usually available from TCC patients, which is not the
case with bronchial biopsies. An alternative diagnostic
tool, which can cope with tiny samples, is RT-PCR,
which allows the accurate measurement of H19
transcript levels.
B. Therapeutic agents
Therapies that target different cancer specific
transcriptional products of the H19-IGF2 loci or
that exploit its transcriptional regulatory elements to
drive the expression of a cytotoxic gene specifically
to tumor cells would be critically advantageous over
the current conventional therapeutic drugs, since
they spare normal cells. Lack of tumor specificity is
mostly responsible for the adverse events caused by
the conventional drugs, which limits greatly the
therapeutic doses. Expression of a DNA-based
therapeutic toxin transcriptionally driven by IGF2-P4
or H19 promoters is predicted to occur in a manner
specific for tumor expressing these gene products.
However, the potential of this transcriptional targeting
approach might be even greater if the cancer-specific
promoters H19, IGF2-P3, and IGF2- P4, are utilized
in the same therapeutic construct because many
tumors that lack H19 gene expression have been
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(Figure 3). Furthermore, the nature, advantage and
disadvantage of these therapeutic approaches are
summarized in Table 1.I. The BC-819 plasmid.
BC-819 is a plasmid vector carrying the H19
promoter, to drive the expression of the A chain of
diphtheria toxin (DT-A), which inflicts damage to
the cells expressing H19 lncRNA specifically by
inhibition of protein synthesis. This engineered toxin
is devoid of the DT-B fragment, thus cannot reenter
neighboring cells. Following pre-clinical animal
model testing in various cancer models (such as
bladder, ovarian, and pancreatic colorectal hepatic
metastasis), clinical trials at various phases of cancer
progression have already been completed.
The drug safety profile was excellent. No serious
adverse events related to the study drug wereure 3 Different therapeutic approaches based on H19-IGF2 gene loc
rapeutic approaches can be harnessed to target specifically lung cancer ce
scriptional targeting approach utilizes transcription factors that activate the e
toxic gene (DT-A) from the therapeutic plasmid vector (BC-819) in a manner
tor in addition to H19-DT-A cassette contains another therapeutic cassette th
Gf2 promoter. Thus BC-821 would increase both the cell killing capacity and
ducts of the H19-IGF2 loci ( e.g. H19, miR-675, P4-IGF2, miR-483), can be spec
sense technologies. The phenotype predicted is retardation of lung cancer gobserved. Toxicity was primarily local and resolved
without sequelae. Subsequently, BC-819 has been
given on compassionate basis to a limited number
of patients afflicted with colorectal hepatic
metastases, pancreatic cancer and relapsed ovarian
ascitic carcinoma. All these cases had no untoward
toxicity and were clinically beneficial (for reviews
see [51,84,85]).
The therapeutic potential of BC-819 for the
treatment of lung cancer in mouse tumor models
was investigated by our group. BC-819 was very
efficient (>90%) in reducing lung cancer cell
growth in vitro. In vivo, aerosolized PEI/BC-819 is
capable of reducing growth only in tumors arising
from the luminal part of the airways that are there-
fore directly accessible for inhaled BC-819 [86].
II. The BC-821 plasmid.
BC-821 is a double promoter (H19 and IGF2-P4)
DT-A-expressing therapeutic vector. Here thei for the treatment options of lung tumorigenesis. Different
lls with aberrant H19/miR-675 and IGF2/miR483 expressions. (Left):
xpression of the endogenous H19 lncRNA to drive the expression of a
specific for tumor expressing H19 gene products. BC-821 therapeutic
at drive the expression of DT-A under the transcriptional control of
the therapeutic index. (Right): Different cancer specific transcriptional
ifically knocked down alone or in combinations utilizing siRNA and
rowth and progression depending on the targeted product.
Table 1 Comparison between different possible therapeutic agents for lung cancer
BC-819 BC-821 siRNA* Anti-miR*
Nature Plasmid DNA. Plasmid DNA. Double stranded RNA. Antisense RNA.
Targeted therapy Yes. Yes. Yes. Yes.
Stability Relatively stable in serum [83-85]. Relatively stable in serum [87,89,90]. Rapidly degraded by serum nuclease. Rapidly degraded by serum nuclease.
Safety Mild safety problems [83-85]. Safe in animal model. In human
subject ND.
ND ND
Homogeneity Very high Very high Depends on manufacturing process. Depends on manufacturing process.
Pharmacokinetics Well established [51,83]. Well established. ND ND
Mode of action Suppresses translation initiation
specifically in cancer cells leading
to cell death.
Suppresses translation initiation
specifically in cancer cells leading
to cell death.
Knockdown target gene mRNA depends
on intrinsic RNAI machinery.
Knockdown target microRNA level depends
on complementary base pairing.
Combinational therapy Can be given alone or in
combination with conventional
drugs.
Can be given alone or in
combination with conventional
drugs.
Can be given alone or in combination
with conventional drugs.
Can be given alone or in combination with
conventional drugs.
Transfection efficiency Low. Low. Bigger plasmid size expected
to have lower transfection efficiency.
High. ND.
Therapeutic index High Very high High ND.
Costs Relatively low Relatively low Relatively high Relatively high
ND: Not determined.
* Could be engineered through DNA plasmid vectors and thus have mostly the characteristics of plasmid vectors.
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regulated by two regulatory sequences, which in
their natural genome position are both proximately
located and are reciprocally imprinted [87]. The
combined expression levels of H19 lncRNA and IGF2
driven by P4 promoter in lung cancer patients is
higher than each one alone, so the use of this vector
should substantially increase the therapeutic index.
In vitro as well as in vivo studies demonstrated that
the double promoter vectors exhibited superior
activity compared to the single promoter vectors in
many cancer models [88-90] including that of the
lung (unpublished data).
III. siRNA and anti-miRs.
This is a relatively new entry into the antineoplastic
arsenal. Double-stranded, small interfering RNA
(siRNA) molecules can specifically ablate the
expression of genes that share their sequence.
Libraries containing siRNA molecules that target all
genes in the human genome are now available.
Pre-clinically, siRNA molecules have been tested in
a NSCLC cell line, to suppress genes responsible for
drug resistance [91]. Furthermore combination of
EGFR inhibitory agents with EGFR-specific siRNA
increases the therapeutic efficacy in NSCLC [92].
In this context, H19-targeted siRNA abrogated
H19-induced multi-drug resistance, via its involvment
in the regulation of MDR1 promoter methylation,
whereas H19 knockdown suppressed MDR1/
P-glycoprotein expression [93]. Furthermore we
recently showed that EMT induced multi-drug
resistance is accompanied by an increase in H19
expression [36]. In our laboratory, siRNA-H19
suppressed anchorage independent growth of lung
cancer cells and also suppressed xenograft bladder
cancer (UMUC3) as well as hepatoma (Hep3B)
growth [36,67]. A potential alternative target could
be IGF2 which may be present in H19-negative
cases, for whom siRNA-IGF2 could be used. It is
also conceivable that dual targeting of both the H19
and IGF2 genes could be employed.
The lung is an attractive target organ for siRNA-based
therapy. While delivery approaches could be
accomplished via systemic (e.g. intravenous) or
pulmonary routes (intranasal, intratracheal or
inhalation), the latter is preferable as it allows higher
retention of siRNA in the lung tissues and also
reduces the risks of systemic toxicity. Large efforts
have been devoted to establish effective siRNA
nanocarriers for direct pulmonary delivery [94-96].
The oncogenic activities of both miR-675 and
miR-483 in lung cancer represent further therapeutic
opportunities whereby antisense oligonucleotides
that can bind directly to these miRNAs can blocktheir activity. This anti-miR approach was found to be
effective in pre-clinical studies for lung cancer [97-99].Summary and future perspectives
It is becoming increasingly clear that H19 and miR-675
are key players in many human cancer types including
those of the lung. H19/miR-675 function can be attrib-
uted to various fundamental aspects of tumorigenesis,
ctoincluding hypoxic stress response, angiogenesis, EMT,
metastasis and multi-drug resistance. The past five years
have witnessed an unprecedented increase in scientific pa-
pers linking H19/miR675 to fundamental signaling path-
ways known to have a pivotal impact on tumorigenesis,
including the hedgehog, p53, HIF-1α, TGF-β, bcR-abl, and
Wnt/β-catenin signaling pathways. Especially notable is
that over the last two years more than ten reports have
been published that linked H19/miR-675 to EMT and the
metastasis process.
Despite this progress, still many questions are left to
be answered. The H19 gene locus is far more complex
than initially thought. Although it is clear that some of
H19 gene functions are performed through miR-675, we
still need to explore what functions can be performed by
H19 that do not involve its miRNA. miR-675 is proc-
essed from H19 lncRNA, but both are up-regulated in
many types of cancers and both can be up-regulated by
common triggers. It remains unclear how this is accom-
plished, taking into consideration that miR-675 is proc-
essed at the expense of H19 lncRNA. One option is that
miR-675 could have its own regulatory sequence, beside
being processed from H19. This has not been investi-
gated yet. Furthermore the interplay between the various
products processed from the H19 gene locus remains
largely unknown.
Whether H19 and miR-675 are secreted in the exo-
somes/body fluids and can be used as diagnostic as well
as prognostic tools in lung cancer patients needs to be
elucidated.
The development of DNA-based therapy involving
H19/miR-675 is underway in our lab, and show promis-
ing results in preclinical models of lung cancer. This will
pave the way for phase I clinical trials in lung cancer
hopefully in the near future.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
IM, DH drafted the manuscript and coordinated the work; MG revised and
critically appraised the manuscript; AH revised, critically appraised and
provided overall supervision for the project. All authors read and approved
the final manuscript.
Acknowledgements
This work was funded by BioCancell Therapeutic. The funder had no role in
study design, decision to publish, or preparation of the manuscript.
Matouk et al. Journal of Translational Medicine  (2015) 13:113 Page 10 of 12Received: 30 November 2014 Accepted: 18 March 2015
References
1. Lima AB, Macedo LT, Sasse AD. Addition of bevacizumab to chemotherapy
in advanced non-small cell lung cancer: a systematic review and meta-analysis.
PLoS One. 2011;6:e22681.
2. Amit L, Ben-Aharon I, Vidal L, Leibovici L, Stemmer S. The impact of
Bevacizumab (Avastin) on survival in metastatic solid tumors–a meta-analysis
and systematic review. PLoS One. 2013;8:e51780.
3. Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA
point of view. RNA Biol. 2012;9:703–19.
4. Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology.
Cancer Discov. 2011;1:391–407.
5. Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new
tale. Cancer Res. 2006;66:7390–4.
6. Enfield KS, Pikor LA, Martinez VD, Lam WL. Mechanistic Roles of Noncoding
RNAs in Lung Cancer Biology and Their Clinical Implications. Genet Res Int.
2012;2012:737416.
7. Gutschner T, Hämmerle M, Eissmann M, Hsu J, Kim Y, Hung G, et al. The
noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype
of lung cancer cells. Cancer Res. 2013;73:1180–9.
8. Thai P, Statt S, Chen CH, Liang E, Campbell C, Wu R. Characterization of a
novel long noncoding RNA, SCAL1, induced by cigarette smoke and
elevated in lung cancer cell lines. Am J Respir Cell Mol Biol. 2013;49:204–11.
9. Chen W, Böcker W, Brosius J, Tiedge H. Mechanistic Roles of Noncoding
RNAs in Lung Cancer Biology and Their Clinical Implications. J Pathol.
1997;183:345–51.
10. Yang Y, Li H, Hou S, Hu B, Liu J, Wang J. The noncoding RNA expression
profile and the effect of lncRNA AK126698 on cisplatin resistance in
non-small-cell lung cancer cell. PLoS One. 2013;8:e65309.
11. Yang F, Huo XS, Yuan SX, Zhang L, Zhou WP, Wang F, et al. Repression of
the long noncoding RNA-LET by histone deacetylase 3 contributes to
hypoxia-mediated metastasis. Mol Cell. 2013;49:1083–96.
12. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, et al. Many
human large intergenic noncoding RNAs associate with chromatin-modifying
complexes and affect gene expression. Proc Natl Acad Sci U S A.
2009;106:11667–72.
13. Nakagawa T, Endo H, Yokoyama M, Abe J, Tamai K, Tanaka N, et al. Large
noncoding RNA HOTAIR enhances aggressive biological behavior and is
associated with short disease-free survival in human non-small cell lung
cancer. Biochem Biophys Res Commun. 2013;436:319–24.
14. Liu Z, Sun M, Lu K, Liu J, Zhang M, Wu W, et al. The long noncoding RNA
HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma
cells via downregualtion of p21(WAF1/CIP1) expression. PLoS One.
2013;8:e77293.
15. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of
mammalian microRNA host genes and transcription units. Genome Res.
2004;14:1902–10.
16. Kim VN. MicroRNA biogenesis: Coordinated cropping and dicing. Nat Rev
Mol Cell Biol. 2005;6:376–85.
17. Hagan JP, O’Neill BL, Stewart CL, Kozlov SV, Croce CM. At least ten genes
define the imprinted Dlk1–Dio3 cluster on mouse chromosome 12qF1.
PLoS One. 2009;4:e4352.
18. Cai X, Cullen BR. The imprinted H19 noncoding RNA is a primary microRNA
precursor. RNA. 2007;13:313–6.
19. Xia T, Liao Q, Jiang X, Shao Y, Xiao B, Xi Y, et al. Long noncoding RNA
associated-competing endogenous RNAs in gastric cancer. Sci Rep. 2014;4:6088.
20. Zhao W, Luo J, Jiao S. Comprehensive characterization of cancer subtype
associated long non-coding RNAs and their clinical implications. Sci Rep.
2014;4:6591.
21. Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet. 2006;1:R17–29.
22. Pauli A, Valen E, Lin MF, Garber M, Vastenhouw NL, Levin JZ, et al.
Systematic identification of long noncoding RNAs expressed during
zebrafish embryogenesis. Genome Res. 2012;22:577–91.
23. Monnier P, Martinet C, Pontis J, Stancheva I, Ait-Si-Ali S, Dandolo L. H19
lncRNA controls gene expression of the Imprinted Gene Network by recruiting
MBD1. Proc Natl Acad Sci U S A. 2013;110:20693–8.
24. Yang J, Lin J, Liu T, Chen T, Pan S, Huang W, et al. Analysis of lncRNA
expression profiles in non-small cell lung cancers (NSCLC) and their clinical
subtypes. Lung Cancer. 2014;85:110–5.25. Zhang L, Zhou XF, Pan GF, Zhao JP. Enhanced expression of long non-coding
RNA ZXF1 promoted the invasion and metastasis in lung adenocarcinoma.
Biomed Pharmacother. 2014;68:401–7.
26. White NM, Cabanski CR, Silva-Fisher JM, Dang HX, Govindan R, Maher CA.
Transcriptome sequencing reveals altered long intergenic non-coding RNAs
in lung cancer. Genome Biol. 2014;15:429.
27. Flynt AS, Lai EC. Biological principles of microRNA-mediated regulation:
shared themes amid diversity. Nat Rev Genet. 2008;9:831–42.
28. Ortholan C, Puissegur MP, Ilie M, Barbry P, Mari B, Hofman P. MicroRNAs and
lung cancer: new oncogenes and tumor suppressors, new prognostic
factors and potential therapeutic targets. Curr Med Chem. 2009;16:1047–61.
29. Kumar MS, Armenteros-Monterroso E, East P, Chakravorty P, Matthews N,
Winslow MM, et al. HMGA2 functions as a competing endogenous RNA to
promote lung cancer progression. Nature. 2014;505:212–7.
30. Zhao B, Han H, Chen J, Zhang Z, Li S, Fang F, et al. MicroRNA let-7c inhibits
migration and invasion of human non-small cell lung cancer by targeting
ITGB3 and MAP4K3. Cancer Lett. 2014;342:43–51.
31. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al.
MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting
DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A. 2007;104:15805–10.
32. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, et al.
Development of a lung cancer therapeutic based on the tumor suppressor
microRNA-34. Cancer Res. 2010;70:5923–30.
33. Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, et al.
The let-7 microRNA reduces tumor growth in mouse models of lung cancer.
Cell Cycle. 2008;7:759–64.
34. Qiao Y, Ma N, Wang X, Hui Y, Li F, Xiang Y, et al. MiR-483-5p controls
angiogenesis in vitro and targets serum response factor. FEBS Lett.
2011;585:3095–4000.
35. Song Q, Xu Y, Yang C, Chen Z, Jia C, Chen J, et al. miR-483-5p promotes
invasion and metastasis of lung adenocarcinoma by targeting RhoGDI1 and
ALCAM. Cancer Res. 2014;74:3031–42.
36. Matouk IJ, Raveh E, Abu-lail R, Mezan S, Gilon M, Gershtain E, et al. Oncofetal
H19 RNA promotes tumor metastasis. Biochim Biophys Acta.
1843;2014:1414–26.
37. Dudek KA, Lafont JE, Martinez-Sanchez A, Murphy CL. Type II collagen
expression is regulated by tissue-specific miR-675 in human articular
chondrocytes. J Biol Chem. 2010;285:24381–7.
38. Keniry A, Oxley D, Monnier P, Kyba M, Dandolo L, Smits G, et al. The H19
lincRNA is a developmental reservoir of miR-675 that suppresses growth
and Igf1r. Nat Cell Biol. 2012;14:659–65.
39. Tsang WP, Ng EK, Ng SS, Jin H, Yu J, Sung JJ, et al. Oncofetal H19-derived
miR-675 regulates tumor suppressor RB in human colorectal cancer.
Carcinogenesis. 2010;31:350–8.
40. Zhuang M, Gao W, Xu J, Wang P, Shu Y. The long non-coding RNA
H19-derived miR-675 modulates human gastric cancer cell proliferation by
targeting tumor suppressor RUNX1. Biochem Biophys Res Commun.
2014;448:315–22.
41. Shi Y, Wang Y, Luan W, Wang P, Tao T, Zhang J, et al. Long non-coding
RNA H19 promotes glioma cell invasion by deriving miR-675. PLoS One.
2014;9:e86295.
42. Kubo T, Yamamoto H, Ichimura K, Jida M, Hayashi T, Otani H, et al. DNA
methylation in small lung adenocarcinoma with bronchioloalveolar
carcinoma components. Lung Cancer. 2009;65:328–32.
43. Wang J, Zhao YC, Lu YD, Ma CP. Integrated bioinformatics analyses identify
dysregulated miRNAs in lung cancer. Eur Rev Med Pharmacol Sci. 2014;18:2270–4.
44. Puisségur MP, Mazure NM, Bertero T, Pradelli L, Grosso S, Robbe-Sermesant
K, et al. miR-210 is overexpressed in late stages of lung cancer and mediates
mitochondrial alterations associated with modulation of HIF-1 activity. Cell
Death Differ. 2011;18:465–78.
45. Grosso S, Doyen J, Parks SK, Bertero T, Paye A, Cardinaud B, et al. MiR-210
promotes a hypoxic phenotype and increases radioresistance in human
lung cancer cell lines. Cell Death Dis. 2013;4:e544.
46. Devlin C, Greco S, Martelli F, Ivan M. miR-210: More than a silent player in
hypoxia. IUBMB Life. 2011;63:94–100.
47. Eilertsen M, Andersen S, Al-Saad S, Richardsen E, Stenvold H, Hald SM, et al.
Positive prognostic impact of miR-210 in non-small cell lung cancer. Lung
Cancer. 2014;83:272–8.
48. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, et al.
hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor
in breast cancer. Clin Cancer Res. 2008;14:1340–8.
Matouk et al. Journal of Translational Medicine  (2015) 13:113 Page 11 of 1249. Pachnis V, Belayew A, Tilghman SM. Locus unlinked to alpha-fetoprotein
under the control of the murine raf and Rif genes. Proc Natl Acad Sci U S A.
1984;81:5523–7.
50. Matouk I, Ayesh B, Schneider T, Ayesh S, Ohana P, De-Groot N, et al.
Oncofetal splice-pattern of the human H19 gene. Biochem Biophys Res
Commun. 2004;318:916–9.
51. Matouk I, Raveh E, Ohana P, Lail RA, Gershtain E, Gilon M, et al. The increasing
complexity of the oncofetal h19 gene locus: functional dissection and
therapeutic intervention. Int J Mol Sci. 2013;14:4298–316.
52. Lustig O, Ariel I, Ilan J, Lev-Lehman E, De-Groot N, Hochberg A. Expression
of the imprinted gene H19 in the human fetus. Mol Reprod Dev.
1994;38:239–46.
53. Berteaux N, Lottin S, Monté D, Pinte S, Quatannens B, Coll J, et al. H19
mRNA-like noncoding RNA promotes breast cancer cell proliferation
through positive control by E2F1. J Biol Chem. 2005;280:29625–36.
54. Matouk IJ, Mezan S, Mizrahi A, Ohana P, Abu-Lail R, Fellig Y, et al.
The oncofetal H19 RNA connection: hypoxia, p53 and cancer. Biochim
Biophys Acta. 1803;2010:443–51.
55. Dugimont T, Montpellier C, Adriaenssens E, Lottin S, Dumont L, Iotsova V,
et al. The H19 TATA-less promoter is efficiently repressed by wild-type
tumor suppressor gene product p53. Oncogene. 1998;16:2395–401.
56. Barsyte-Lovejoy D, Lau SK, Boutros PC, Khosravi F, Jurisica I, Andrulis IL, et al.
The c-Myc oncogene directly induces the H19 noncoding RNA by allele-
specific binding to potentiate tumorigenesis. Cancer Res. 2006;66:5330–7.
57. Chan LH, Wang W, Yeung W, Deng Y, Yuan P, Mak KK. Hedgehog signaling
induces osteosarcoma development through Yap1 and H19 overexpression.
Oncogene. 2014;33:4857–66.
58. Guo G, Kang Q, Chen Q, Chen Z, Wang J, Tan L, et al. High expression of
long non-coding RNA H19 is required for efficient tumorigenesis induced
by Bcr-Abl oncogene. FEBS Lett. 2014;588:1780–6.
59. Adriaenssens E, Lottin S, Berteaux N, Hornez L, Fauquette W, Fafeur V, et al.
Cross-talk between mesenchyme and epithelium increases H19 gene
expression during scattering and morphogenesis of epithelial cells. Exp Cell
Res. 2002;275:215–29.
60. Luo M, Li Z, Wang W, Zeng Y, Liu Z, Qiu J. Long non-coding RNA H19
increases bladder cancer metastasis by associating with EZH2 and inhibiting
E-cadherin expression. Cancer Lett. 2013;333:213–21.
61. Kallen AN, Zhou XB, Xu J, Qiao C, Ma J, Yan L, et al. The imprinted H19
lncRNA antagonizes let-7 microRNAs. Mol Cell. 2013;52:101–12.
62. Ma C, Nong K, Zhu H, Wang W, Huang X, Yuan Z, et al. H19 promotes
pancreatic cancer metastasis by derepressing let-7′s suppression on its
target HMGA2-mediated EMT. Tumour Biol. 2014;35:9163–9.
63. Dey BK, Pfeifer K, Dutta A. The H19 long noncoding RNA gives rise to
microRNAs miR-675-3p and miR-675-5p to promote skeletal muscle
differentiation and regeneration. Genes Dev. 2014;28:491–501.
64. Gao Y, Wu F, Zhou J, Yan L, Jurczak MJ, Lee HY, et al. The H19/let-7
double-negative feedback loop contributes to glucose metabolism in
muscle cells. Nucleic Acids Res. 2014;2:13799–811.
65. Yan L, Zhou J, Gao Y, Ghazal S, Lu L, Bellone S, et al. Regulation of
tumor cell migration and invasion by the H19/let-7 axis is antagonized
by metformin-induced DNA methylation. Oncogene. 2014.
doi:10.1038/onc.2014.236.
66. Runge S, Nielsen FC, Nielsen J, Lykke-Andersen J, Wewer UM, Christiansen J.
H19 RNA binds four molecules of insulin-like growth factor II mRNA-binding
protein. J Biol Chem. 2000;275:29562–9.
67. Matouk IJ, DeGroot N, Mezan S, Ayesh S, Abu-lail R, Hochberg A, et al. The
H19 non-coding RNA is essential for human tumor growth. PLoS One.
2007;2:e845.
68. Ayesh S, Matouk I, Schneider T, Ohana P, Laster M, Al-Sharef W, et al.
Possible physiological role of H19 RNA. Mol Carcinog. 2002;35:63–74.
69. Dugimont T, Curgy JJ, Wernert N, Delobelle A, Raes MB, Joubel A, et al. The
H19 gene is expressed within both epithelial and stromal components of
human invasive adenocarcinomas. Biol Cell. 1995;85:117–24.
70. Sadiq AA, Salgia R. MET as a possible target for non-small-cell lung cancer.
J Clin Oncol. 2013;31:1089–96.
71. Kondo M, Suzuki H, Ueda R, Osada H, Takagi K, Takahashi T, et al. Frequent
loss of imprinting of the H19 gene is often associated with its
overexpression in human lung cancers. Oncogene. 1995;10:1193–8.
72. Kaplan R, Luettich K, Heguy A, Hackett NR, Harvey BG, Crystal RG.
Monoallelic up-regulation of the imprinted H19 gene in airway epithelium
of phenotypically normal cigarette smokers. Cancer Res. 2003;63:1475–82.73. Chen B, Yu M, Chang Q, Lu Y, Thakur C, Ma D, et al. Mdig de-represses H19
large intergenic non-coding RNA (lincRNA) by down-regulating H3K9me3
and heterochromatin. Oncotarget. 2013;4:1427–37.
74. Berteaux N, Aptel N, Cathala G, Genton C, Coll J, Daccache A, et al. A novel
H19 antisense RNA overexpressed in breast cancer contributes to paternal
IGF2 expression. Mol Cell Biol. 2008;28:6731–45.
75. Deng Q, He B, Gao T, Pan Y, Sun H, Xu Y, et al. Up-regulation of 91H
promotes tumor metastasis and predicts poor prognosis for patients with
colorectal cancer. PLoS One. 2014;9:e103022.
76. Vu TH, Chuyen NV, Li T, Hoffman AR. Loss of imprinting of IGF2 sense and
antisense transcripts in Wilms’ tumor. Cancer Res. 2003;63:1900–5.
77. Rabinowits G, Gerçel-Taylor C, Day JM, Taylor DD, Kloecker GH. Exosomal
microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer.
2009;10:42–6.
78. Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED, Harris CC.
Circulating micro-RNA expression profiles in early stage nonsmall cell lung
cancer. Int J Cancer. 2012;130:1378–86.
79. Zandberga E, Kozirovskis V, Abols A, Andrējeva D, Purkalne G, Linē A.
Cell-free microRNAs as diagnostic, prognostic, and predictive biomarkers for
lung cancer. Genes Chromosomes Cancer. 2013;52:356–69.
80. Yu L, Todd NW, Xing L, Xie Y, Zhang H, Liu Z, et al. Early detection of lung
adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer.
2010;127:2870–8.
81. Xie Y, Todd NW, Liu Z, Zhan M, Fang H, Peng H, et al. Altered miRNA
expression in sputum for diagnosis of non-small cell lung cancer. Lung
Cancer. 2010;67:170–6.
82. Kim NH, Choi SH, Kim CH, Lee CH, Lee TR, Lee AY. Reduced MiR-675 in
exosome in H19 RNA-related melanogenesis via MITF as a direct target.
J Invest Dermatol. 2014;134:1075–82.
83. Gofrit ON, Benjamin S, Halachmi S, Leibovitch I, Dotan Z, Lamm DL, et al.
DNA Based Therapy with Diphtheria Toxin-A BC-819: A Phase 2b Marker
Lesion Trial in Patients with Intermediate Risk Nonmuscle Invasive Bladder
Cancer. J Urol. 2014;191:1697–702.
84. Matouk I, Evantal N, Amit D, Ohana P, Gofrit O, Sorin V, Birman T, Gershtain E,
Hochberg A. The H19-IGF2 Role in Bladder Cancer Biology and DNA-Based
Therapy, Bladder Cancer - From Basic Science to Robotic Surgery. ISBN:
978-953-307-839-7, intech, doi:10.5772/29236.
85. Ohana P, Matouk I, Amit D, Gilon M, Hochberg A. Toxin-based cancer gene
therapy under the control of oncofetal H19 regulatory sequences. 3rd.
edition. gene therapy of cancer. 2014; 107–122. ISBN: 978-0-12-394295-1.
86. Hasenpusch G, Pfeifer C, Aneja MK, Wagner K, Reinhardt D, Gilon M, et al.
Aerosolized BC-819 inhibits primary but not secondary lung cancer growth.
PLoS One. 2011;6:e20760.
87. Amit D, Tamir S, Hochberg A. Development of targeted therapy for a broad
spectrum of solid tumors mediated by a double promoter plasmid
expressing diphtheria toxin under the control of IGF2-P4 and IGF2-P3
regulatory sequences. Int J Clin Exp Med. 2013;6:110–8.
88. Amit D, Matouk IJ, Lavon I, Birman T, Galula J, Abu-Lail R, et al. Transcriptional
targeting of glioblastoma by diphtheria toxin-A driven by both H19 and
IGF2-P4 promoters. Int J Clin Exp Med. 2012;5:124–35.
89. Amit D, Hochberg A. Development of targeted therapy for bladder cancer
mediated by a double promoter plasmid expressing diphtheria toxin under
the control of H19 and IGF2-P4 regulatory sequences. J Transl Med.
2010;8:134.
90. Amit D, Hochberg A. Development of targeted therapy for a broad spectrum of
cancers (pancreatic cancer, ovarian cancer, glioblastoma and HCC) mediated by a
double promoter plasmid expressing diphtheria toxin under the control of H19
and IGF2-P4 regulatory sequences. Int J Clin Exp Med. 2012;5:296–305.
91. Ganesh S, Iyer AK, Weiler J, Morrissey DV, Amiji MM. Combination of
siRNA-directed Gene Silencing With Cisplatin Reverses Drug Resistance in
Human Non-small Cell Lung Cancer. Mol Ther Nucleic Acids. 2013;2:e110.
92. Chen G, Kronenberger P, Teugels E, Umelo IA, De Grève J. Targeting the
epidermal growth factor receptor in non-small cell lung cancer cells: the
effect of combining RNA interference with tyrosine kinase inhibitors or
cetuximab. BMC Med. 2012;10:28.
93. Tsang WP, Kwok TT. Riboregulator H19 induction of MDR1-associated drug
resistance in human hepatocellular carcinoma cells. Oncogene.
2007;26:4877–81.
94. Shim G, Choi HW, Lee S, Choi J, Yu YH, Park DE, et al. Enhanced intrapulmonary
delivery of anticancer siRNA for lung cancer therapy using cationic
ethylphosphocholine-based nanolipoplexes. Mol Ther. 2013;21:816–24.
Matouk et al. Journal of Translational Medicine  (2015) 13:113 Page 12 of 1295. Xu CX, Jere D, Jin H, Chang SH, Chung YS, Shin JY, et al. Poly(ester amine)-
mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung
tumorigenesis. Am J Respir Crit Care Med. 2008;178:60–73.
96. Beyerle A, Braun A, Merkel O, Koch F, Kissel T, Stoeger T. Comparative
in vivo study of poly(ethylene imine)/siRNA complexes for pulmonary
delivery in mice. J Control Release. 2011;151:51–6.
97. Li YJ, Zhang YX, Wang PY, Chi YL, Zhang C, Ma Y, et al. Regression of A549
lung cancer tumors by anti-miR-150 vector. Oncol Rep. 2012;27:129–34.
98. Fiori ME, Barbini C, Haas TL, Marroncelli N, Patrizii M, Biffoni M, et al.
Antitumor effect of miR-197 targeting in p53 wild-type lung cancer. Cell
Death Differ. 2014;21:774–82.
99. Shi Y, Liu C, Liu X, Tang DG, Wang J. The microRNA miR-34a inhibits
non-small cell lung cancer (NSCLC) growth and the CD44hi stem-like NSCLC
cells. PLoS One. 2014;9:e90022.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
